BioWorld - Wednesday, January 21, 2026

Articles Tagged with ''Huntington’s disease''

Speech Vitals-ALS mobile app

FDA grants Aural Analytics breakthrough device designation

March 29, 2023
By Annette Boyle
Aural Analytics Inc. received a breakthrough device designation from the U.S. FDA for its Speech Vitals-ALS technology, a software application that collects and analyzes speech recordings to help monitor amyotrophic lateral sclerosis (ALS) in adults in clinic and home settings. The software could improve management of the devastating disease.
Read More
White Euro symbol on blue background
Newco news

Teitur Trophics targeting neurodegenerative disease with €28M series A round

March 14, 2023
By Nuala Moran
Newco Teitur Trophics ApS has raised €28 million (US$30.1 million) in a series A with which it will lay out a new route to targeting sortilin in the treatment of neurodegenerative diseases. The company is targeting the sortilin-related Vps10p domain containing receptor, which plays a role in regulating a number of pathways involved in the control of neuronal viability and function.
Read More
Neurology/Psychiatric

Series A financing at Teitur Trophics to fund neurodegenerative disease pipeline

March 14, 2023
Teitur Trophics ApS, a spinout from Aarhus University seeded by the Bioinnovation Institute in 2020, has completed a €28 million (US$30.1 million) series A financing. Teitur has developed a platform of first-in-class cyclic peptides with a novel mechanism that preserves neuronal function, and these peptides have the potential to treat a broad range of neurodegenerative diseases.
Read More

GBS navigation system directs Annexon toward pivotal study; effort in HD on track, too

Jan. 19, 2023
By Randy Osborne
Upcoming catalysts from Annexon Biosciences Inc. put some joy into shares as the firm talked up its prospects during the recent J.P. Morgan Healthcare Conference, where attendees heard Jan. 8 about the news ahead with C1q protein complex inhibitor ANX-005 in Huntington’s disease (HD) as well as progress in Guillain-Barre syndrome (GBS), and more. The stock (NASDAQ:ANNX) enjoyed a 43% stock boost in the days after JPM, rising from $4.79 on Jan 8 to $6.84 on Jan. 13.
Read More